PEL.NS

Piramal Enterprises Limited [PEL.NS] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

PEL.NS Stock Summary

Earnings have grown 9.24% per last year.

EPS has been increasing for the past 3 years (Yearly statements)

EPS has been increasing for the past 3 quarters (Quarter statements)

PEL.NS's dividend payments are well covered by cash flows with cash payout ratio of 30.12%.

Earnings are expected to fall -5.57% next year

PEL.NS has less than 1 year of cash runway

An RSI reading of 30 or below indicates an oversold or undervalued condition.

Top 10 Correlated ETFs

PEL.NS

Top 10 Correlated Stocks

PEL.NS

In the News

PEL.NS Financial details

Company Rating

Buy

Market Cap

155.05B

Income

26.15B

Revenue

116.99B

Book val./share

Cash/share

Dividend

Dividend %

5.08%

Employees

13.56K

Optionable

Shortable

Yes

Earnings

24 May 2023

P/E

5.93

Forward P/E

3.24

PEG

0.62

P/S

1.33

P/B

P/C

P/FCF

Quick Ratio

0.13

Current Ratio

Debt / Equity

LT Debt / Equity

EPS (TTM)

109.56

EPS next Y

200.44

EPS next Q

EPS this Y

44.33%

EPS next Y

82.95%

EPS next 5Y

82.95%

EPS last 5Y

-21.67%

Revenue last 5Y

5.65%

Revenue Q/Q

10.57%

EPS Q/Q

-330.78%

SMA20

-19.91%

SMA50

-18.03%

SMA100

-20.28%

Inst Own

Inst Trans

ROA

ROE

12%

ROC

0.2%

Gross Margin

88%

Oper. Margin

53%

Profit Margin

22%

Payout

Shs Outstand

238.66M

Shs Float

112.94M

Target Price

52W Range

645.0-2380.5

52W High

-72.7%

52W Low

+0.72%

RSI

27.27

Rel Volume

1.01

Avg Volume

1.24M

Volume

1.26M

Perf Week

-3.43%

Perf Month

-22.39%

Perf Quarter

-24.83%

Perf Half Y

-32.03%

Beta

0.686261

Volatility

14.74%, 75.73%

Prev Close

-2.47%

Price

649.65002

Change

-3.18%

PEL.NS Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-03-31

Metric	2018-03-31	2019-03-31	2020-03-31	2021-03-31	2022-03-31
Revenue per share	570.98	649.53	620.02	540.19	590.12
Net income per share	275.07	72.4	1.14	56.19	81.1
Operating cash flow per share	-857.54	-570.01	356.61	154.54	368.98
Free cash flow per share	-901.52	-604.01	334.28	129.44	328.56
Cash per share	408.81	162.63	390.33	429.44	469.65
Book value per share	1.42K	1.34K	1.45K	1.43K	1.5K
Tangible book value per share	941.18	895.9	1.26K	1.32K	1.36K
Share holders equity per share	1.42K	1.34K	1.45K	1.43K	1.5K
Interest debt per share	2.53K	2.97K	2.24K	1.84K	2.54K
Market cap	449.12B	534.96B	198.02B	415.72B	518.57B
Enterprise value	866.81B	1087.14B	576.99B	754.1B	1011.2B
P/E ratio	8.77	36.32	824.05	31.2	26.97
Price to sales ratio	4.22	4.05	1.52	3.25	3.71
POCF ratio	-2.81	-4.61	2.63	11.34	5.93
PFCF ratio	-2.68	-4.35	2.81	13.54	6.66
P/B Ratio	1.7	1.96	0.65	1.22	1.46
PTB ratio	1.7	1.96	0.65	1.22	1.46
EV to sales	8.15	8.23	4.42	5.89	7.23
Enterprise value over EBITDA	15.35	15.2	7.49	9.4	13.34
EV to operating cash flow	-5.43	-9.37	7.68	20.58	11.56
EV to free cash flow	-5.16	-8.85	8.19	24.57	12.98
Earnings yield	0.11	0.03	0	0.03	0.04
Free cash flow yield	-0.37	-0.23	0.36	0.07	0.15
Debt to equity	1.75	2.14	1.45	1.23	1.78
Debt to assets	0.64	0.68	0.59	0.54	0.63
Net debt to EBITDA	7.4	7.72	4.92	4.22	6.5
Current ratio	0.54	0.39	0.68	1.49	1.3
Interest coverage	1.6	1.56	1.17	1.69	1.45
Income quality	-3.12	-7.87	312.79	2.75	4.55
Dividend Yield	0.01	0.01	0.03	0.01	0.02
Payout ratio	0.07	0.3	23.17	0.24	0.41
Sales general and administrative to revenue	0.02	0.02	0.02	0.03	0
Research and developement to revenue	0.02	0.02	0.01	0.01	0
Intangibles to total assets	0.12	0.11	0.05	0.05	0.05
Capex to operating cash flow	0.05	0.06	-0.06	-0.16	-0.11
Capex to revenue	-0.08	-0.05	-0.04	-0.05	-0.07
Capex to depreciation	-1.71	-1.33	-0.71	-1.06	-1.44
Stock based compensation to revenue	0	0	0	0	0
Graham number	2.96K	1.48K	192.89	1.35K	1.65K
ROIC	0.17	0.05	-0.04	0.04	0.06
Return on tangible assets	0.08	0.02	0	0.02	0.02
Graham Net	-2.05K	-2.69K	-1.69K	-1.31K	-2.16K
Working capital	-99.13B	-188.07B	-75.6B	65.2B	56.13B
Tangible asset value	175.24B	182.28B	265.2B	312.68B	321.64B
Net current asset value	-344.11B	-460.9B	-282.24B	-221.12B	-387.24B
Invested capital	1.67	2.06	1.38	1.16	1.57
Average receivables	0	0	0	0	0
Average payables	8.19B	9.16B	9.74B	10.84B	14.37B
Average inventory	7.49B	8.05B	9.48B	11.8B	14.16B
Days sales outstanding	0	0	0	0	0
Days payables outstanding	86.58	87.55	103.33	117.64	244.6
Days of inventory on hand	76.65	76.38	110.78	129.7	221.08
Receivables turnover	0	0	0	0	0
Payables turnover	4.22	4.17	3.53	3.1	1.49
Inventory turnover	4.76	4.78	3.29	2.81	1.65
ROE	0.19	0.05	0	0.04	0.05
Capex per share	-43.97	-34.01	-22.33	-25.1	-40.42

Quarterly Fundamentals Overview

Last date of statement is 2022-12-31 for Q3

Metric	2022-03-31	2022-06-30	2022-09-30	2022-12-31	2022-12-31
Revenue per share	174.44	148.68	79.34	159.91	87.73
Net income per share	4.59	20.79	-64.37	35.83	148.55
Operating cash flow per share	0	0	0	0	0
Free cash flow per share	0	0	0	0	0
Cash per share	466.66	0	1.19K	252.76	0
Book value per share	1.49K	0	1.15K	0	0
Tangible book value per share	1.35K	0	1.14K	0	0
Share holders equity per share	1.49K	0	1.15K	0	0
Interest debt per share	2.39K	0	2.02K	54.23	0
Market cap	521.9B	395.16B	206.28B	197.7B	197.71B
Enterprise value	1014.53B	0	644.62B	137.38B	0
P/E ratio	119.2	19.91	-3.36	5.78	1.39
Price to sales ratio	12.54	11.14	10.89	5.18	9.44
POCF ratio	0	0	0	0	0
PFCF ratio	0	0	0	0	0
P/B Ratio	1.47	0	0.75	0	0
PTB ratio	1.47	0	0.75	0	0
EV to sales	24.37	0	34.04	3.6	0
Enterprise value over EBITDA	64.98	0	-53.62	5.34	0
EV to operating cash flow	0	0	0	0	0
EV to free cash flow	0	0	0	0	0
Earnings yield	0	0.01	-0.07	0.04	0.18
Free cash flow yield	0	0	0	0	0
Debt to equity	1.78	0	1.93	0	0
Debt to assets	0.63	0	0.66	1	0
Net debt to EBITDA	31.55	0	-36.46	-2.35	0
Current ratio	1.3	0	19.77	0	0
Interest coverage	1.46	1.41	1.34	1.54	1.59
Income quality	0	0	0	0	0
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0	0	0	0	0
Research and developement to revenue	0	0	0	0	0
Intangibles to total assets	0.05	0	0	0	0
Capex to operating cash flow	0	0	0	0	0
Capex to revenue	0	0	0	0	0
Capex to depreciation	0	0	0	0	0
Stock based compensation to revenue	0	0	0	0	0
Graham number	391.75	0	1.29K	0	0
ROIC	0.02	0	0.01	0.02	0
Return on tangible assets	0	0	-0.02	0.01	0
Graham Net	-2.14K	0	-1.02K	-3.01K	0
Working capital	56.13B	0	715.75B	-467.09B	0
Tangible asset value	321.64B	0	271.06B	0	0
Net current asset value	-387.24B	0	224.72B	-779.5B	0
Invested capital	1.57	0	1.72	0	0
Average receivables	0	0	0	0	0
Average payables	8.48B	0	0	8.8B	0
Average inventory	7.67B	0	0	7.72B	0
Days sales outstanding	0	0	0	0	0
Days payables outstanding	181.66	0	4.6K	0	0
Days of inventory on hand	164.2	0	0	0	0
Receivables turnover	0	0	0	0	0
Payables turnover	0.5	0	0.02	0	0
Inventory turnover	0.55	0	0	0	0
ROE	0	0	-0.06	0	0
Capex per share	0	0	0	0	0

PEL.NS Dividend History

PEL.NS Frequently Asked Questions

What is Piramal Enterprises Limited stock symbol ?

Piramal Enterprises Limited is a IN stock and trading under the symbol PEL.NS

What is Piramal Enterprises Limited stock quote today ?

Piramal Enterprises Limited stock price is $649.65002 today.

Is Piramal Enterprises Limited stock public?

Yes, Piramal Enterprises Limited is a publicly traded company.

Something similar

Top by Market Cap

EMBASSY.NS

AMZ.DE

MSF.BR

Company Profile

Volume Average 1.24M
Market Capitalization 155.05B
Employee 13.56K
CEO Mr. Ajay Gopikisan Piramal
Headquarters Mumbai,IN
IPO Date 1994-11-03
Website https://www.piramal.com/businesses/piramal-enterprises/

Piramal Enterprises Limited operates in financial services and pharmaceuticals businesses in India, North America, Europe, Japan, and internationally. It operates through Pharmaceuticals Manufacturing and Services, and Financial Services segments. The company provides housing finance and other financing solutions, such as private equity, structured debt, senior secured debt, construction finance, and flexi lease rental discounting to real estate sector; and funding solutions to infrastructure, renewable energy, roads, industrials, auto components, and other sectors. It also operates distressed asset investing platform that invests in equity and/or debt in assets. In addition, the company offers contract development and manufacturing solutions, including drug discovery, production, and manufacturing of active pharmaceutical ingredients and formulations; and inhalation and injectable anaesthesia, injectable pain, antibiotics, and other medications, as well as intrathecal spasticity management drugs. Further, it provides over-the-counter products comprising analgesics, skin care, kids' wellness, digestives, women's health, disinfectant, Covifind, and hygiene and protection products, as well as vitamins, minerals, and supplements primarily under the Saridon, Lacto Calamine, Little's, I-Pill, Supradyn, Polycrol, Triactiv, Ourdaily, Pulse Oximeters, and Tetmosol brands. The company was formerly known as Piramal Healthcare Limited and changed its name to Piramal Enterprises Limited in July 2012. Piramal Enterprises Limited was incorporated in 1947 and is based in Mumbai, India.